BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ping M, Wang S, Guo Y, Jia J. TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability. Biochem Biophys Res Commun 2022;586:177-84. [PMID: 34856418 DOI: 10.1016/j.bbrc.2021.07.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 An R, Li Y, Lin Y, Xu F, Li M, Liu Z. EZH1/2 as targets for cancer therapy. Cancer Gene Ther 2022. [DOI: 10.1038/s41417-022-00555-1] [Reference Citation Analysis]
2 Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J, Xu Z. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. Cancer Commun (Lond) 2023;43:123-49. [PMID: 36353796 DOI: 10.1002/cac2.12386] [Reference Citation Analysis]
3 Wu Z, Wang Y, Yu Z, Meng Z, Duan W, Zhang W, Fang J. TRIM21‑a potential biomarker for the prognosis of thyroid cancer. Exp Ther Med 2022;24:761. [PMID: 36561971 DOI: 10.3892/etm.2022.11697] [Reference Citation Analysis]
4 Huang N, Sun X, Li P, Liu X, Zhang X, Chen Q, Xin H. TRIM family contribute to tumorigenesis, cancer development, and drug resistance. Exp Hematol Oncol 2022;11:75. [PMID: 36261847 DOI: 10.1186/s40164-022-00322-w] [Reference Citation Analysis]